ArticleFrontiers in immunology2026
Vitamin D supports activated CD4
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vitamin D (VitD) is an important immunometabolic regulator of T cell function. Its active form, 1,25-dihydroxyvitamin D Methods: Human CD4 Results: VitD-treated cultures exhibited increased cell numbers despite reduced glucose uptake and lactate production, indicating proliferation partially independent of classical glycolytic metabolism. Proteomic analysis revealed increased expression of glutaminase, glutamate dehydrogenase, and CD38, together with enrichment of Selenium Metabolism and Selenoproteins and Nicotinate and Nicotinamide Metabolism, suggesting enhanced glutaminolysis and NAD+ remodeling. Consistently, tritiated and ¹³C-glutamine tracing demonstrated increased glutamine uptake and incorporation into glutamate, α-ketoglutarate, glucose, and inositol-related metabolites, supporting a glutaminolysis-dependent anabolic program rather than oxidative phosphorylation. Pharmacological inhibition of VDR (MeTC7, 1 nM), glutamine uptake (GPNA, 250 µM), or glutaminase activity (BPTES and compound 968, 5 µM) significantly reduced T cell expansion, highlighting glutamine metabolism as essential for the VitD-mediated cell expansion. Interestingly, prolonged cultures showed that VitD ultimately restricted proliferation at day 7; however, supplementation with glutamine and VitD restored cell expansion, suggesting that VitD promotes a metabolically restrained but adaptive proliferative state. Discussion: Overall, our findings identify glutaminolysis as a central metabolic pathway supporting VitD-induced CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.